[Vaccination against COVID-19]

Klin Mikrobiol Infekc Lek. 2021 Jun;27(2):49-60.
[Article in Czech]

Abstract

Vaccination is essential to manage the COVID-19 pandemic. Vaccination significantly protects against severe COVID-19, hospitalization and death; it also protects against symptomatic infection and reduces the risk of transmission to other people. Protection against the new SARS-CoV-2 variants may be lower, but protection against severe course and death remains high. Two mRNA vaccines (BNT162b2 and mRNA-1273) and two vector vaccines (AZD1222 and Ad26.COV2.S) are currently available in the Czech Republic. Vaccination of persons over 60 years of age and immunocompromised persons, who are demonstrably at the highest risk of a serious course of the disease, is of the utmost importance. In order to achieve adequate vaccination coverage, it is necessary to motivate other groups of people to be vaccinated, including children over 12 years of age and young adults. Vaccination is also recommended in pregnant women in the 2nd and 3rd trimesters and in breastfeeding women. For selected groups of vaccines, a third dose of vaccination is recommended (additional third dose 4 weeks after the second dose or a booster dose 8 to 12 months after the second dose). The side effects are usually mild, with serious complications (including anaphylaxis, thrombocytopenia with thrombosis syndrome, myocarditis, Guillain-Barré syndrome and capillary leak syndrome) being rare.

MeSH terms

  • Aged
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • ChAdOx1 nCoV-19
  • Child
  • Female
  • Humans
  • Middle Aged
  • Pandemics
  • Pregnancy
  • Pregnancy Complications, Infectious*
  • SARS-CoV-2
  • Vaccination
  • Young Adult

Substances

  • COVID-19 Vaccines
  • ChAdOx1 nCoV-19
  • BNT162 Vaccine